Niosome in Ocular Drug Delivery: An Update Review
- August 11, 2018
- Posted by: RSIS
- Category: Pharmacy
International Journal of Research and Scientific Innovation (IJRSI) | Volume V, Issue VIII, August 2018 | ISSN 2321–2705
Niosome in Ocular Drug Delivery: An Update Review
Savita More*, Namita Phalke, Sarika Lokhande, Snehal Badadare, Vijay Raje
GES College of Pharmacy (D. Pharm), Limb, Satara, Maharashtra, India
Abstract:-With the recent advancement in the field of ocular therapy, drug delivery approaches have been superior to a new concept in terms of nonionic surfactant vesicles (NSVs), that is, the ability to deliver the therapeutic agent to a patient in a staggered profile. However the major drawbacks of the conventional drug delivery system like lacking of permeability through ocular barrier and poor bioavailability of water soluble drugs have been overcome by the emergence of NSVs. Niosomes have the same potential advantages of phospholipid vesicles (liposomes) of being able to accommodate both water soluble and lipid soluble drug molecules control their release and as such serve as versatile drug delivery devices of numerous applications. The drug loaded NSVs (DNSVs) can be fabricated by simple and cost-effective techniques with improved physical stability and enhance bioavailability without blurring the vision. The increasing research interest surrounding this delivery system has widened the areas of pharmaceutics in particular with many more subdisciplines expected to coexist in the near future. This review gives a comprehensive emphasis on NSVs considerations, formulation approaches, physicochemical properties, fabrication techniques, and therapeutic significances of NSVs in the field of ocular delivery and also addresses the future development of modified NSVs.
Keywords: – nonionic surfactant, physical stability, bioavailability.
I. INTRODUCTION
Ocular drug delivery has been a foremost challenge for researchers because of the distinctive anatomy and physiology of eye which contains different barriers such as different layers of cornea, sclera and retina in addition to blood retinal barriers, lachrymal fluid-eye barrier and also drug loss from the ocular surface. These obstacles cause a considerable challenge for delivery of a drug alone or in a dosage form, especially to the posterior segment of the eye. The major challenge to the formulator is to outwit these barriers without causing any tissue damage.